Works matching DE "ANTINEOPLASTIC combined chemotherapy protocols"

Results: 392
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.

    Published in:
    JNCI Cancer Spectrum, 2024, v. 8, n. 4, p. 1, doi. 10.1093/jncics/pkae054
    By:
    • Ramaswamy, Anant;
    • Bhargava, Prabhat;
    • Dubashi, Biswajit;
    • Gupta, Anuj;
    • Kapoor, Akhil;
    • Srinivas, Sujay;
    • Shetty, Omshree;
    • Jadhav, Poonam;
    • Desai, Veena;
    • Noronha, Vanita;
    • Joshi, Amit;
    • Menon, Nandini;
    • Patil, Vijay M;
    • Mishra, Bal Krishna;
    • Sansar, Bipinesh;
    • Singh, Arpita;
    • Patel, Swapnil;
    • Singh, Satyendra Narayan;
    • Dhal, Ipsita;
    • Vinayak, Kunal Ranjan
    Publication type:
    Article
    20
    21

    Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy.

    Published in:
    Clinical & Translational Immunology, 2021, v. 10, n. 11, p. 1, doi. 10.1002/cti2.1351
    By:
    • Shanavas, Mohamed;
    • Law, Soi‐Cheng;
    • Hertzberg, Mark;
    • Hicks, Rodney J;
    • Seymour, John F;
    • Li, Zhixiu;
    • Merida de Long, Lilia;
    • Nath, Karthik;
    • Sabdia, Muhammed B;
    • Gunawardana, Jay;
    • Gandhi, Maher K;
    • Keane, Colm
    Publication type:
    Article
    22
    23
    24
    25

    Protective effects of ascorbic acid against anticancer drug-induced oxidative stress and genotoxic damage in Saccharomyces cerevisiae.

    Published in:
    3 Biotech, 2025, v. 15, n. 5, p. 1, doi. 10.1007/s13205-025-04280-y
    By:
    • da Mata, Ana Maria Oliveira Ferreira;
    • Silva, Reyca Rodrigues e;
    • Braga, Antônio Lima;
    • de Carvalho, Ricardo Melo;
    • de Oliveira Santos, José Victor;
    • de Alencar, Marcus Vinícius Oliveira Barros;
    • Paz, Márcia Correia Fernanda Jardim;
    • Ansari, Siddique Akber;
    • Ansari, Irfan Aamer;
    • Islam, Muhammad Torequl;
    • de Castro e Sousa, João Marcelo;
    • da Silva, Felipe Cavalcanti Carneiro;
    • de Carvalho Melo Cavalcante, Ana Amélia;
    • da Silva, Benedito Borges
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33

    Assessing the Therapeutic Impacts of HAMLET and FOLFOX on BRAF-Mutated Colorectal Cancer: A Study of Cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo.

    Published in:
    Medicina (1010660X), 2024, v. 60, n. 1, p. 142, doi. 10.3390/medicina60010142
    By:
    • Žilinskas, Justas;
    • Stukas, Darius;
    • Jasukaitienė, Aldona;
    • Žievytė, Inga;
    • Balion, Zbigniev;
    • Šapauskienė, Jurgita;
    • Banienė, Rasa;
    • Paužas, Henrikas;
    • Lizdenis, Paulius;
    • Čėsna, Vaidotas;
    • Dambrauskas, Žilvinas;
    • Gulbinas, Antanas;
    • Tamelis, Algimantas
    Publication type:
    Article
    34
    35
    36

    Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

    Published in:
    PLoS Medicine, 2024, v. 21, n. 5, p. 1, doi. 10.1371/journal.pmed.1004389
    By:
    • Wang, De-Shen;
    • Ren, Chao;
    • Li, Shan-Shan;
    • Fong, William Pat;
    • Wu, Xiao-Jun;
    • Xiao, Jian;
    • Li, Bin-Kui;
    • Zheng, Yun;
    • Ding, Pei-Rong;
    • Chen, Gong;
    • Qiu, Miao-Zhen;
    • Wang, Zhi-Qiang;
    • Wang, Feng-Hua;
    • Luo, Hui-Yan;
    • Wang, Feng;
    • Wang, Xiao-Zhong;
    • Wang, Ling-Yun;
    • Xie, De-Jin;
    • Chen, Tao;
    • Li, Li-Ren
    Publication type:
    Article
    37

    Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.

    Published in:
    Hematological Oncology, 2023, v. 41, n. 4, p. 655, doi. 10.1002/hon.3184
    By:
    • Nizzoli, Maria E.;
    • Manni, Martina;
    • Ghiggi, Chiara;
    • Pulsoni, Alessandro;
    • Musuraca, Gerardo;
    • Merli, Michele;
    • Califano, Catello;
    • Bari, Alessia;
    • Massaia, Massimo;
    • Conconi, Annarita;
    • Musto, Pellegrino;
    • Mannina, Donato;
    • Perrone, Tommasina;
    • Re, Francesca;
    • Galimberti, Sara;
    • Gini, Guido;
    • Capponi, Monia;
    • Vitolo, Umberto;
    • Usai, Sara V.;
    • Stefani, Piero M.
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 421, doi. 10.1002/hon.3164_309
    By:
    • Minson, A.;
    • Verner, E.;
    • Giri, P.;
    • Wong, S. M.;
    • Ratnasingam, S.;
    • Butler, J.;
    • Janowski, W.;
    • Ku, M.;
    • Cheah, C. Y.;
    • Hertzberg, M.;
    • Herbert, K.;
    • Hamad, N.;
    • Yannakou, C. K.;
    • Neeson, P.;
    • Saghebi, J.;
    • Blombery, P.;
    • Robertson, M.;
    • Lau, L. S.;
    • Xie, J.;
    • Seymour, J. F.
    Publication type:
    Article
    49
    50